- Home
- Publications
- Publication Search
- Publication Details
Title
Current management and novel agents for malignant melanoma
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 5, Issue 1, Pages 3
Publisher
Springer Nature
Online
2012-02-14
DOI
10.1186/1756-8722-5-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
- (2011) Yuan Yuan et al. Journal of Hematology & Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Ovarian cancer immunotherapy: opportunities, progresses and challenges
- (2010) Bei Liu et al. Journal of Hematology & Oncology
- First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
- (2010) Guoqing Wei et al. Journal of Hematology & Oncology
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
- (2010) Christophe Frémin et al. Journal of Hematology & Oncology
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
- (2010) Jiahuai Tan et al. Journal of Hematology & Oncology
- Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data
- (2010) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current systemic therapy for metastatic melanoma
- (2009) Sanjiv S Agarwala Expert Review of Anticancer Therapy
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started